GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Notes Receivable

KYTX (Kyverna Therapeutics) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Notes Receivable?

Kyverna Therapeutics's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Kyverna Therapeutics Notes Receivable Historical Data

The historical data trend for Kyverna Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Notes Receivable Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kyverna Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Kyverna Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics Headlines

From GuruFocus